Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

NCT02783625 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Relapsed/Refractory T-cell Lymphomas

Interventions

DRUG: Romidepsin
DRUG: Bortezomib
DRUG: duvelisib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]